In Brief: Genentech v. Novo Nordisk and BTG
Genentech v. Novo Nordisk and BTG: Human growth hormone patent infringement complaint dismissed with prejudice against Genentech by the International Trade Commission Jan. 17 after it agrees with the ALJ's Nov. 30 recommendation ("The Pink Sheet" Dec. 5, 1994, T&G-3). Both Novo and Biotechnology General have filed for declaratory judgments that their products do not infringe Genentech patents and those patents are unenforceable and invalid...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth